Literature DB >> 10973385

Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients.

J Rüdiger Siewert1, M Feith, M Werner, H J Stein.   

Abstract

OBJECTIVE: To assess the outcome of surgical therapy based on a topographic/anatomical classification of adenocarcinoma of the esophagogastric junction. SUMMARY BACKGROUND DATA: Because of its borderline location between the stomach and esophagus, the choice of surgical strategy for patients with adenocarcinoma of the esophagogastric junction is controversial.
METHODS: In a large single-center series of 1,002 consecutive patients with adenocarcinoma of the esophagogastric junction, the choice of surgical approach was based on the location of the tumor center or tumor mass. Treatment of choice was esophagectomy for type I tumors (adenocarcinoma of the distal esophagus) and extended gastrectomy for type II tumors (true carcinoma of the cardia) and type III tumors (subcardial gastric cancer infiltrating the distal esophagus). Demographic data, morphologic and histopathologic tumor characteristics, and long-term survival rates were compared among the three tumor types, focusing on the pattern of lymphatic spread, the outcome of surgery, and prognostic factors in patients with type II tumors.
RESULTS: There were marked differences in sex distribution, associated intestinal metaplasia in the esophagus, tumor grading, tumor growth pattern, and stage distribution between the three tumor types. The postoperative death rate was higher after esophagectomy than extended total gastrectomy. On multivariate analysis, a complete tumor resection (R0 resection) and the lymph node status (pN0) were the dominating independent prognostic factors for the entire patient population and in the three tumor types, irrespective of the surgical approach. In patients with type II tumors, the pattern of lymphatic spread was primarily directed toward the paracardial, lesser curvature, and left gastric artery nodes; esophagectomy offered no survival benefit over extended gastrectomy in these patients.
CONCLUSION: The classification of adenocarcinomas of the esophagogastric junction into type I, II, and III tumors shows marked differences between the tumor types and provides a useful tool for selecting the surgical approach. For patients with type II tumors, esophagectomy offers no advantage over extended gastrectomy if a complete tumor resection can be achieved.

Entities:  

Mesh:

Year:  2000        PMID: 10973385      PMCID: PMC1421149          DOI: 10.1097/00000658-200009000-00007

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  34 in total

1.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

2.  Adenocarcinoma of the gastroesophageal junction in Japan: relevance of Siewert's classification applied to 177 cases resected at a single institution.

Authors:  Y Kodera; Y Yamamura; Y Shimizu; A Torii; T Hirai; K Yasui; T Morimoto; T Kato
Journal:  J Am Coll Surg       Date:  1999-12       Impact factor: 6.113

Review 3.  Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy.

Authors:  S R DeMeester; T R DeMeester
Journal:  Ann Surg       Date:  2000-03       Impact factor: 12.969

4.  Frequency and clinical impact of lymph node micrometastasis and tumor cell microinvolvement in patients with adenocarcinoma of the esophagogastric junction.

Authors:  J D Mueller; H J Stein; T Oyang; S Natsugoe; M Feith; M Werner; J Rüdiger Siewert
Journal:  Cancer       Date:  2000-11-01       Impact factor: 6.860

5.  Cardia carcinoma considered as a distinct clinical entity.

Authors:  B Husemann
Journal:  Br J Surg       Date:  1989-02       Impact factor: 6.939

6.  Histogenetical investigations on adenocarcinomas of the esophagogastric junction. An immunohistochemical study.

Authors:  M Sarbia; F Borchard; K J Hengels
Journal:  Pathol Res Pract       Date:  1993-06       Impact factor: 3.250

7.  Adenocarcinoma of the gastric cardia. The choice of gastrectomy.

Authors:  D N Papachristou; J G Fortner
Journal:  Ann Surg       Date:  1980-07       Impact factor: 12.969

8.  Adenocarcinoma of the distal esophagus and gastric cardia. Comparison of results of transhiatal esophagectomy and thoracoabdominal esophagogastrectomy.

Authors:  D Goldfaden; M B Orringer; H D Appelman; R Kalish
Journal:  J Thorac Cardiovasc Surg       Date:  1986-02       Impact factor: 5.209

9.  Difference in main lymphatic pathways from the lower esophagus and gastric cardia.

Authors:  T Aikou; H Shimazu
Journal:  Jpn J Surg       Date:  1989-05

10.  [Cardia cancer: attempt at a therapeutically relevant classification].

Authors:  J R Siewert; A H Hölscher; K Becker; W Gössner
Journal:  Chirurg       Date:  1987-01       Impact factor: 0.955

View more
  193 in total

1.  Preoperative chemotherapy unmasks underlying Barrett's mucosa in patients with adenocarcinoma of the distal esophagus.

Authors:  J Theisen; H J Stein; H J Dittler; M Feith; C Moebius; W K H Kauer; M Werner; J R Siewert
Journal:  Surg Endosc       Date:  2002-01-09       Impact factor: 4.584

Review 2.  Pattern of lymphatic spread of Barrett's cancer.

Authors:  Marcus Feith; Hubert J Stein; J Rüdiger Siewert
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

3.  Outcomes of Abdominal Total Gastrectomy for Type II and III Gastroesophageal Junction Tumors: Single Center's Experience in Korea.

Authors:  Kyoung Tai Kim; Oh Jeong; Mi Ran Jung; Seong Yeop Ryu; Young-Kyu Park
Journal:  J Gastric Cancer       Date:  2012-03-30       Impact factor: 3.720

Review 4.  Thoracoscopic esophagectomy in the prone position.

Authors:  Omar A Jarral; Sanjay Purkayastha; Thanos Athanasiou; Ara Darzi; George B Hanna; Emmanouil Zacharakis
Journal:  Surg Endosc       Date:  2012-03-07       Impact factor: 4.584

Review 5.  Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies.

Authors:  Shinichi Hasegawa; Takaki Yoshikawa
Journal:  Gastric Cancer       Date:  2010-07-03       Impact factor: 7.370

Review 6.  Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction.

Authors:  Kei Hosoda; Keishi Yamashita; Natusya Katada; Masahiko Watanabe
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-08-01

7.  Prognoses of advanced esophago-gastric junction cancer may be modified by thoracotomy and splenectomy.

Authors:  Kei Hosoda; Keishi Yamashita; Harukazu Tsuruta; Hiromitsu Moriya; Hiroaki Mieno; Akira Ema; Marie Washio; Masahiko Watanabe
Journal:  Oncol Lett       Date:  2017-11-17       Impact factor: 2.967

8.  Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer.

Authors:  Michael Stahl; Hansjochen Wilke; Martin Stuschke; Martin K Walz; Ulrich Fink; Michael Molls; J Rüdiger Siewert; Michael Schroeder; Hans-Bruno Makoski; Ulrich Schmidt; Siegfried Seeber; Udo Vanhoefer
Journal:  J Cancer Res Clin Oncol       Date:  2004-10-05       Impact factor: 4.553

Review 9.  Carcinoma of the gastroesophageal junction in Chinese patients.

Authors:  Qin Huang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

Review 10.  Surgical management of esophagogastric junction tumors.

Authors:  Burkhard H A von Rahden; Hubert J Stein; J Rüdiger Siewert
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.